Dalia Burzyn

OPKO Health (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index3.7kcitations34works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Extracellular vesicles in disease(9), Monoclonal and Polyclonal Antibodies Research(7), Immune Cell Function and Interaction(7), Immune cells in cancer(7), CAR-T cell therapy research(7)

Publications34 total

MDX-2001–101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors
Future Oncology·2026Open Access
MDX-2001–101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors
Figshare·2026Open Access
MDX-2001–101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors
Figshare·2026Open Access
1156 MDX2004, a novel immune rejuvenator targeting CD3, CD28, and 4–1BB, augments tumor immunity in preclinical animal models
Regular and Young Investigator Award Abstracts·2025Open Access
843 First-in-human dosing model for MDX2004, a novel trispecific CD3xCD28/4–1BB antibody-fusion protein for advanced malignancies
Regular and Young Investigator Award Abstracts·2025Open Access
1584TiP A phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors
Annals of Oncology·2025
A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors.
Journal of Clinical Oncology·2025· 1 cited
1287 Preclinical characterization of MDX2001, a novel tetraspecific T cell engager (CD3/CD28) targeting TROP2 and c-MET in solid tumor malignancies
Regular and Young Investigator Award Abstracts·2024Open Access
1317 A quantitative systems pharmacology model for first-in-human dosing of MDX2001, a multispecific antibody for the treatment of advanced solid tumors
Regular and Young Investigator Award Abstracts·2024Open Access
680TiP A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
Annals of Oncology·2024· 2 cited
1345 exoASO-C/EBPβ™: An engineered exosome therapeutic that selectively targets MDSCs and induces potent single-agent anti-tumor activity in checkpoint refractory tumor models
Regular and Young Investigator Award Abstracts·2022Open Access
1344 Preclinical PK/PD profile, biomarker identification and rationale for indication selection of exoASO-STAT6™, a selective tumor-associated macrophage targeting candidate
Regular and Young Investigator Award Abstracts·2022Open Access
Abstract 3508: Exosome-mediated delivery of antisense oligonucleotides targeting C/EBPβ reprograms tumor-associated macrophages and induces potent single agent anti-tumor activity
Cancer Research·2022
Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity
Science Advances·2022· 226 citedOpen Access
842 Exosome mediated reprogramming of tumor associated macrophages by exoASO-STAT6 for the treatment of hepatocellular carcinoma (HCC)
Regular and Young Investigator Award Abstracts·2021· 1 citedOpen Access
Abstract 1792: Engineered exosome- mediated STAT6 knockdown in tumor associated macrophages (TAMs) results in potent single agent activity in a hepatocellular carcinoma (HCC) model
Cancer Research·2021· 4 cited
A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties
Molecular Therapy·2021· 290 citedOpen Access
703 Engineered exosomes with altered cellular tropism achieve targeted STING agonist delivery and single-agent tumor control in vivo
Regular and Young Investigator Award Abstracts·2020· 1 citedOpen Access
Abstract 5696: Genetic reprogramming of TAMs by engineered exosomes results in potent single agent anti-tumor activity
Cancer Research·2020
Abstract A50: Reprogramming of tumor-associated M2 macrophages with antisense oligonucleotide-loaded exosomes results in potent single-agent antitumor activity
Cancer Immunology Research·2020· 5 cited
page 1 of 2Next →

Frequent Co-authors

Charan Leng(10), Olga Burenkova(9), Su Chul Jang(9), Kyriakos D. Economides(8), Timothy Soos(8), Kerry Culm(8), Sushrut Kamerkar(7), Kelvin Zhang(7), Isabel Piazzón(7), Monette Cotreau(7), Diane Mathis(6), Sriram Sathyanarayanan(6), Tong Zi(6), Irene Nepomnaschy(6), Anna Minchom(6), Lukas Makris(6), Christophe Benoıst(5), William K. Dahlberg(5), Anne-Laure Goenaga(5), Ronnie R. Wei(5)